Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen (CGEN) announced that management will participate in a virtual H.C. Wainwright drug discovery conference fireside chat on October 8, 2026.
The 3rd Annual AI Based Drug Discovery & Development Conference runs October 8–9. The chat is scheduled for 9:30 AM ET. A live webcast will be available on Compugen's investor relations events page at www.cgen.com, with a replay following the event.
Compugen (CGEN) will host a virtual key opinion leader event on October 5, 2026 at 8:00 AM ET to discuss COM701 and the treatment landscape in ovarian cancer.
The event will feature Dr. Oladapo Yeku of Harvard Medical School and Massachusetts General Hospital, who will present the randomized MAIA-ovarian adaptive platform trial design of COM701, a potential first-in-class anti-PVRIG antibody, in maintenance treatment of relapsed platinum-sensitive ovarian cancer. Median progression-free survival data from the trial’s interim analysis are expected by Q1 2027. Compugen’s team will also provide an update on expanded capabilities of its Unigen™ AI/ML-powered target discovery platform, followed by a live Q&A session.
Compugen (CGEN) will participate in a fireside chat and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, held September 14-16, 2026.
The fireside chat is scheduled for Monday, September 14, 2026 at 3:30 PM ET, with a live webcast and replay available on the events page of Compugen’s Investor Relations website. Compugen is a clinical-stage cancer immunotherapy company using its AI-powered Unigen™ platform and is advancing an immuno-oncology pipeline that includes COM701 in an ovarian cancer trial, rilvegostomig being developed by AstraZeneca under an exclusive license, and GS-0321 licensed to Gilead and in a Phase 1 trial.
Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/NYSE:AZN) have dosed the first patient in the global phase 3 TROPION-Urothelial04 trial. The study evaluates Datroway (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus standard adjuvant options (durvalumab, nivolumab, or enfortumab vedotin plus pembrolizumab) in high-risk muscle invasive urothelial cancer (MIUC) after surgery.
The open-label, three-arm trial will randomize about 915 patients worldwide. The primary endpoint is investigator-assessed disease-free survival for Datroway plus rilvegostomig versus standard of care; key secondary endpoints include overall survival, multiple recurrence-free measures, patient-reported outcomes and safety. According to Daiichi Sankyo, the TIGIT component of rilvegostomig is derived from Compugen’s (Nasdaq/TASE:CGEN) clinical-stage antibody COM902.
Datroway, a TROP2-directed DXd antibody-drug conjugate, is already approved at 6 mg/kg in numerous countries for specific advanced breast cancer and EGFR-mutated NSCLC indications, and is being studied in more than 20 trials across lung, breast and urothelial cancers.
Compugen (NASDAQ/TASE: CGEN) reported Q2 2026 revenues of $2.6 million, up from $1.3 million in Q2 2025, mainly from recognition of Gilead license payments. Net loss was $7.0 million (‑$0.07 per share) versus $7.3 million (‑$0.08) a year earlier. R&D expenses rose to $6.3 million, G&A expenses were stable at $2.3 million.
As of June 30, 2026, Compugen held $125.3 million in cash, deposits and marketable securities, reported no debt, and expects its cash runway to fund operations into 2029. The COM701 MAIA‑ovarian trial is progressing with a median PFS interim analysis expected by Q1 2027. Partner AstraZeneca reported first overall survival data for rilvegostomig in biliary tract cancer, and Gilead‑partnered GS‑0321 Phase 1 continues as planned.
Compugen (NASDAQ/TASE: CGEN), a clinical-stage cancer immunotherapy company, announced that management will present and hold 1x1 meetings at the BTIG Biotechnology Conference 2026, taking place virtually from July 28-29, 2026. Investors are invited to contact their BTIG representative to request a meeting, and no replay will be available.
According to Compugen, its pipeline includes COM701, currently in a randomized ovarian cancer maintenance trial; rilvegostomig, a PD-1/TIGIT bispecific antibody developed by AstraZeneca under an exclusive license; and GS-0321, licensed to Gilead and in a Phase 1 trial conducted by Compugen.
Compugen (NASDAQ: CGEN; TASE: CGEN) will release its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open, and will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.
Investors can join by dialing 1-866-744-5399 in the U.S. or +972-3-918-0644 internationally, or via live webcast on Compugen’s website, where a replay will also be available. Compugen is a clinical-stage cancer immunotherapy company leveraging its AI/ML Unigen platform and developing assets including COM701, rilvegostomig and GS-0321 in collaboration with partners such as AstraZeneca and Gilead.
Compugen (Nasdaq:CGEN) presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.
The trial evaluates COM701 as maintenance treatment in relapsed platinum-sensitive ovarian cancer, with initial data expected by Q1 2027.
Compugen (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company, will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, June 17-19, 2026.
The poster, presented by Dr. Oladapo Yeku on June 18, 2026, covers COM701 maintenance treatment in relapsed platinum sensitive ovarian cancer and will later be available on Compugen's website.
Compugen (Nasdaq:CGEN), a clinical-stage cancer immunotherapy company using AI/ML for computational target discovery, will participate in Jones Trading's “Mapping the Path from Target to Patient” Fireside Chat Series with leaders in AI/ML-based drug development.
The event is scheduled for Monday, June 15, 2026, from 10:30–11:00 AM ET, with a live webcast and replay available via Compugen's investor relations website.